Cite
Sanagawa A, Hotta Y, Kataoka T, et al. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Med. 2018;7(6):2269-2279doi: 10.1002/cam4.1429.
Sanagawa, A., Hotta, Y., Kataoka, T., Maeda, Y., Kondo, M., Kawade, Y., Ogawa, Y., Nishikawa, R., Tohkin, M., & Kimura, K. (2018). Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer medicine, 7(6), 2269-2279. https://doi.org/10.1002/cam4.1429
Sanagawa, Akimasa, et al. "Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System." Cancer medicine vol. 7,6 (2018): 2269-2279. doi: https://doi.org/10.1002/cam4.1429
Sanagawa A, Hotta Y, Kataoka T, Maeda Y, Kondo M, Kawade Y, Ogawa Y, Nishikawa R, Tohkin M, Kimura K. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Med. 2018 Jun;7(6):2269-2279. doi: 10.1002/cam4.1429. Epub 2018 Apr 16. PMID: 29663729; PMCID: PMC6010750.
Copy
Download .nbib
